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Abstract: The first Meeting on “Molecular Origins of Lung Cancer – Prospects for Personalized
Prevention and Therapy” was held from January 10 to 14, 2010 in San Diego, California. The
purpose of the meeting was to discuss important basic, translational, and clinical work aimed at
improving lung cancer prevention, detection, and treatment. Topics included drug design, target
identification, early detection, cancer stem cells, microRNAs, genome wide approaches to deter-
mining risk and outcome, mouse models, and tumor microenvironment. The role of cancer
advocates in supporting research was an important component of the meeting. Meeting presentations
demonstrated that emerging technologies can molecularly dissect lung cancers that have important
relevance for clinical utility. This includes molecular based strategies not only for treatment of
established cancers but also individualized and molecularly-based strategies for cancer risk reduc-
tion and chemoprevention.
INTRODUCTION
It is now apparent that translational science using genomic and proteomic technol-
ogies can define the molecular pathways that drive cancer progression for lung cancer.
This knowledge in turn translates into more effective therapies that target these driver
pathways in patients. Continued progress, however, is critical given the large incidence
and death rates associated with lung cancer. Our understanding of these molecular
pathways in lung cancer continues to evolve and new targets have been identified. In
addition, clinical trials are keeping pace with laboratory studies. Progress in the under-
standing of non-small cell lung cancer (NSCLC) biology and advancement of care will
depend upon the identification and integration of genetic changes in tumors coupled with
interactions with stromal elements within tumor microenvironment. The rapid progress in
whole genome sequencing will contribute to this progress as will use of other ‘omic
technologies that accurately profile the state of human lung cancers. This meeting was the
first partnership between International Association for the Study of Lung Cancer (IASLC)
or American Association for Cancer Research (AACR) to create a dedicated meeting
focused on the discovery and translation of new pathways important in lung cancer
biology.
The keynote address was delivered by Dr. Tyler Jacks who presented an overview
of how mouse models of lung cancer can be used to pilot strategies for early detection,
chemoprevention, or therapy. A review of previous work with K-Ras mouse models was
presented along with models of advanced lung cancer with K-Ras activation crossed with
p53 loss. A few vignettes of ongoing work were presented. The first used K-Ras/p53
model to examine cisplatin sensitivity and resistance and found that lung cancers
regressed independently of p53 activity. The most interesting finding was that rapid repair
of DNA damage mediates resistance to cisplatin chemotherapy. Overall this work suggests
that inhibiting DNA repair mechanisms may be one strategy to overcome resistance to
cisplatin and possibly other DNA damaging agents. A second line of work revealed how
these models can help understand and therapeutically manipulate metastasis. Lung cancers
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developing in the K-Ras/p53 model can metastasize to liver
and adrenal sites similar to human tumors. A novel system to
activate tumors using lentivirus was developed that allows for
molecular tagging of tumors facilitating the ability to track
lineages of primary and metastatic tumors. This could ulti-
mately be used to understand biologic differences between
primary and metastatic sites as well as differences between
primary tumors that do or do not metastasize. Early work was
described using gene expression profiling that yields insights
into differences between primary tumors that do or do not
metastasize. One of the genes that was reported included
NKX2–1 or TTF-1. Both in vitro and in vivo studies sug-
gested that TTF-1 can in some contexts act as a metastasis
suppressor in lung cancer. Therefore, through these models,
novel and rationale strategies to treat lung cancers can be
developed and translated to the clinic.
Tyrosine Kinase Signaling and Targeted
Therapy
This session focused on an established clinical target,
epidermal growth factor receptor (EGFR), two new clinical
targets: EML4-ALK and the insulin-like growth factor recep-
tor 1 (IGF1R). The presence of an activating kinase domain
EGFR mutation (“mutant EGFR”) predicts clinical response
to EGFR tyrosine kinase inhibitors (TKIs). Three studies
published in 2009 demonstrate that EGFR TKIs are superior
to chemotherapy in EGFR mutant patients (1–3). These
studies also demonstrate that patients with wild type (wt)
EGFR rarely have partial responses to EGFR TKIs. Although
EGFR mutations predict sensitivity to TKIs, all patients
develop resistance. There are two defined categories for
NSCLC tumors to develop resistance to EGFR TKIs: by
developing a second mutation that allows EGFR activation
despite the presence of an inhibitor (T790M) or by enhancing
alternative signaling pathways (i.e., c-Met or IGF-1R) that
allow for the activation of downstream signaling pathways
(e.g. PI3K/AKT) despite EGFR inhibition. The T790M mu-
tation is found in about half of mutant EGFR NSCLC tumors
in which EGFR TKI resistance develops. Zhou, et. al. have
developed EGFR inhibitors that inhibit T790M EGFR more
effectively than wt EGFR (7). These agents are effective in
vitro and in mice and hold promise for treating patients who
develop resistance to EGFR TKIs. c-Met amplification is
found in about 10 % of patients with acquired resistance to
EGFR TKIs. In mouse models of acquired resistance, the
combination of EGFR and c-Met inhibition obliterates such
tumors (8).
A key clinical question is whether or not one can
predict the mechanism of EGFR resistance prospectively.
Transient exposure to the c-Met ligand hepatocyte growth
factor (HGF) results in resistance to EGFR inhibition via
activation of the c-Met pathway. One would predict that
removal of HGF would restore EGFR TKI sensitivity and
indeed this happens in most cell lines. However, in HCC827
cells a transient exposure to HGF led to c-Met amplification
and resistance to EGFR TKIs. c-Met amplification was
present in 0.01 % of HCC827 cells. This was not due to
contamination because re-isolation of cells derived from
single HCC827 cells also developed the same 0.01 % of cells
with c-Met amplification. Incubation with HGF simply se-
lected for the pre-existing population. The key questions are
if this phenomenon exists in human tumors and, if so, can one
predict the resistance mechanism before it emerges by iden-
tifying this population? Both EGFR and c-Met are receptor
tyrosine kinases that, when activated by their ligands, can
lead to the activation of downstream signaling pathways.
However, there is also evidence for lateral signaling between
c-Met and EGFR. One study suggested that EGFR activates
c-Met in a c-Src-dependent, ligand-independent manner (11).
Another key question is whether inhibition of down-
stream pathways, such as PI3K or AKT, can overcome
resistance? A single agent PI3K inhibitor was ineffective in
NSCLC (with T790M-L858R EGFR) in vitro. However a
combination of MAPK and PIK inhibition was effective. This
is distinct from HER2-amplified breast cancer cells where
PI3K inhibition alone is effective (9). In the NSCLC cells, the
inhibition of PI3K led to a decrease in Mcl-1 and the inhibi-
tion of MAPK led to an increase in BIM – both were required
to achieve apoptosis.
In addition to EGFR, novel fusion genes between the
echinoderm microtubule-associated protein-like 4 and ana-
plastic lymphoma kinase (EML4-ALK) are potent drivers of
lung cancer growth and survival (4). Laboratory and clinical
studies demonstrate the transforming power of EML4-ALK
and the critical role of ALK kinase in this process. Expression
of EML4-ALK in trangeneic mice leads to the development
of multiple lung adenocarcinomas (5). The formation of
adenocarcinomas is inhibited by ALK kinase inhibition.
Likewise, treatment of patients with NSCLC tumors that
possess EML4-ALK with an ALK / c-Met inhibitor (PF-
02341066) led to a partial response in 17 of 29 (59 %)
evaluable patients and stable disease in 7 of 29 (24 %) - many
patients were heavily pre-treated (6).Testing for the EML4-
ALK fusion protein is technically challenging. EML4-ALK
can be fused at different sites – 12 have been identified so far,
making standard polymerase chain reaction (PCR) assays
problematic. Standard immunohistochemistry (IHC) is diffi-
cult because protein expression is relatively low. Fluores-
cence in situ hybridization (FISH) assays have been used but
are also technically challenging because the EML4 and ALK
genes are both located on the short arm of chromosome 2 and
the inversion is small.
A second novel target is the insulin-like growth factor
receptor 1 (IGF-1R). An understanding of the normal phys-
iology of the insulin and insulin-like growth factor (IGF)
signaling pathways is important in order to understand the
toxic effects of drugs targeting IGF-1R and the design of
biomarkers. Components of the network include the ligands
insulin, IGF1 and IGF2; IGF binding proteins that affect
ligand availability; 2 IGF receptors: IGF-1R and IGF-2R, and
2 insulin receptors (A and B). There are at least 24 drugs in
development that target IGF-IR and 12 in clinical trial. These
fall into 2 broad categories: antibodies that target IGF-IR and
small molecule TKIs (10). Antibodies are more specific and
were designed to avoid affecting the insulin receptor. Most of
the TKIs also have significant activity against the insulin
receptor. This difference in specificity could affect efficacy
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and toxicity. One would expect that IGF-1R TKIs would
cause profound diabetes due to the inhibition of the insulin
receptors. However, significant metabolic disturbances have
not been observed likely due to poor drug accumulation in the
muscle. A phase II study of the anti-IGF1R monoclonal
antibody CP-751,871 in combination with paclitaxel and
carboplatin demonstrated that the combination was safe in
patients with NSCLC. Response rates for the combination
were high – especially in those with squamous carcinoma.
However, in December 2009, the phase III study of the
combination of chemotherapy and CP-751,871 for front line
treatment of NSCLC was terminated because an interim
analysis suggested that the addition of CP-751,871 to che-
motherapy was unlikely to improve overall survival. Possible
next steps to increase the tolerability and efficacy of anti-
IGF-1R therapy include: exclusion of diabetics; combination
with metformin, which may have anti-cancer properties of its
own via reduction in circulating insulin levels; combinations
with non-chemo regimens; combinations with regimens that
do not require steroids; and an exploration of biomarkers to
define host-tumor interactions that may predict tolerability
and efficacy. Possible biomarkers include circulating levels
of IGF-BPs and tumor amplification of IGF-1R.
Early Detection for Premalignant Lesions and
Field Cancerization
Assuming that lung cancer progresses sequentially
through stages I-IV, detecting more early stage cancers suit-
able for surgical or radiotherapeutic intervention offers the
greatest chance of increasing the cure rate among those
affected by the disease. Defining who to screen and how to
screen for early stage lung cancers continues to be discussed.
Although previous radiographic screening studies have raised
the possibility that radiographically detected early stage lung
cancers could represent a different (milder) clinical condition,
rather than the initial event in a sequential stage progression,
the National Lung Screening Trial (NLST) is set to answer
this question definitively. Beginning in August 2002, the
NLST randomizing 53,476 high risk men and women (greater
than or equal to 30 pack years, and if a former smoker having
quit more than or equal to 15 years previously) to either 3
annual chest x-rays or 3 annual low dose helical CT scans of
the chest. The study was sized to detect a 20% difference in
lung cancer specific mortality with 90% power. Secondary
endpoints included all course mortality, lung cancer preva-
lence and incidence and the stage distribution of any detected
cancers. Biospecimen collected during the NLST include
plasma, buffy coat, sputum, urine and any subsequently
resected tumors, that could be used to validate biomarkers
that may help distinguish benign from malignant nodules, or
assist in detecting tumors in the first place are now available
for analysis. ACRIN will organize applications for research
on these specimens from March 2010.
Detecting premalignant lesions or premalignant field
changes offers two possible advantages – firstly to redefine a
high risk cohort to apply other screening tests to. Secondly,
assuming that, like stage, carcinogenesis also progresses
sequentially, should effective chemopreventatives be devel-
oped, the detection of premalignant disease could trigger
specific interventions designed to reverse these changes.
Affymetrix chips have been used to identify the most com-
monly altered genes in the bronchial epithelium of smokers
compared to non-smokers. Of these, several genes persist
among those who have quit smoking, suggesting that these
may be more associated with long term carcinogenic risk.
Using an 80 gene airway signature as an adjunct to standard
cytology/biopsies at bronchoscopy the combination had a
positive predictive value of 84% and a negative predictive
value of 95%. This combination is now being explored
prospectively in 800 subjects undergoing bronchoscopy in-
ternationally. Additional research directions include explor-
ing the potential for applying the same gene signatures to
cells derived from the nasal or buccal mucosa; whether
microRNAs can be used instead of microarrays; and whether
whole RNA sequencing technologies (RNA-Seq) which can
address both mRNAs and miRNAs will add additional useful
information.
Other early detection strategies include exploring other
early markers of epigenetic change potenitally leading to
carcinogenesis, such as covalent histone modifications, that
have been described in several established cancers. The least
invasive techniques include exploring volatile organic com-
pounds in exhaled breath, which appear to distinguish be-
tween non-small cell and small cell lung cancer cell lines
when the air above tissue culture dishes are analysed. How-
ever, since most of these compounds are simple metabolites,
how well they would distinguish a cancer in vivo in the
presence of multiple normal cells remains to be seen. Blood
derived assays include bead-based multiplex immunoassays
looking at multiple different pro-angiogenic, inflammatory
and pro-tumorigenic cytokines. When the blood profiles of 40
such cytokines were compared between 28 stage I lung
cancer patients and 58 high risk smokers, logistic regression
identified a 3 marker distinguishing classifier (IL-2, IL-3 and
macrophage derived chemokine (MDC)) that will now be
explored prospectively to evaluate its utility in more accu-
rately defining indeterminate pulmonary nodules pre-proce-
dure.
Detection and Prevention: From Mouse to
Man
With advances in our understanding of the molecular
basis of lung cancer tumorigenesis, investigators are design-
ing and conducting trials which target this biology for che-
moprevention. The initial step looks to define molecular
pathways which are integral to the process of lung carcino-
genesis and identify potential effective agents to target groups
at risk. Metastatic lung cancer models that delineate the
process of tumor progression have guided researchers to
evaluate the tumor microenvironment and the role of epithe-
lial to mesenchymal transition (EMT) in the metastatic po-
tential of lung tumors and pre-malignant lesions. The zinc-
finger transcription factor, Snail, is a transcriptional repressor
of E-cadherin and its overexpression in lung cancer and pre-
malignant lesions can lead to EMT, angiogenesis and tumor
growth (12). A murine model that develops adenocarcinoma due
to expression of mutant K-ras and p53 demonstrated the ability
for tumor cells to transition between epithelial and mesenchymal
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states(13). MicroRNA (miR)-200 expression led to inhibition of
EMT, which could be reversed by signaling through the Notch
pathway. Furthermore, evaluating cells that demonstrate EMT
potential has led to the identification of lung cancer self-renew-
ing cells with elevated CD133 and aldehyde dehydrogenase
(ALDH) levels, which may be targeted for therapy and preven-
tion. In a murine model, iloprost inhibition of prostacylin syn-
thase led to a decrease in tumor formation (14). Extending this
therapy in a randomized trial demonstrated a reduction in bron-
chial dysplasia, which was evident in former smokers, but did
not benefit current smokers. In addition to targeting signaling
pathways for chemoprevention, a novel method to inhibit tumor
growth through epigenetic modulation was discussed. Methyl-
ation of the promoter region of four genes has been shown to be
associated with early recurrence in early stage lung cancer (15),
and this data has been used to initiate a trial combining meth-
ylation inhibition and histone deacetylase inhibition to poten-
tially inhibit the progression of self-renewing cancer cells.
Other Thoracic Cancers
As molecular testing paired with molecular targeted
therapies is starting to change treatment paradigms in non-
small cell lung cancer, the same principles are also starting to
be explored in other, rarer cancers of the thorax. Comparative
Genomic Hybridization (CGH) arrays applied to small cell
lung cancers suggest gene copy number alterations relating to
the FAK and neuroendocrine pathways commonly occur.
Following on from this lead, phosphorylated FAK has been
detected in small cell lung cancer cell lines independent of
cell adhesion. Given that FAK inhibitors are in clinical
development and interfere with small cell lung cancer cell
line morphology in vitro, the possibility of exploring FAK
inhibitors in small cell lung cancer in a clinical trial is being
considered.
In mesothelioma, pemetrexed with cisplatinum pro-
duces far higher responses rates than cisplatinum does alone.
One of the major molecular targets of pemetrexed is thymi-
dylate synthase (TS). High levels of TS have been seen in
squamous cancer of the lung in association with a lower
response to pemetrexed. Using a bespoke IHC scoring system
for TS, 40 mesotheliomas were assessed and showed a range
of different levels (35% high, 47.5% low, 17.5% negative.
However, correlation with clinical outcomes following pem-
etrexed treatment is awaited. Also in mesothelioma, cell lines
vary by whether they are sensitive to Vesicular Stomatitis
Virus (VSV), an oncolytic virus, and whether beta-IFN pro-
tects the cells from the virus (as it does in most non-malignant
cells). Markers associated with the IFN pathway can be
assessed by IHC and demonstrate heterogeneity on mesothe-
lioma tissue microarrays raising the possibility that such
markers, notably P48, could be explored to assess which
mesotheliomas may respond to IFN, and which may be
resistant to IFN but susceptible to oncolytic viruses such as
VSV. Again, clinical validation of these hypotheses is
awaited. In a recent Italian series, ERCC1 expression by IHC
did not correlate with response to platinum containing ther-
apy in mesotheliomas. MTOR was also noted to be variably
expressed I mesotheliomas, raising the possibility of using
MTOR inhibitors in this disease. No activating mutations in
PI3Kinase were noted among the mesotheliomas to explain
the MTOR over-expression, and no other mutations were
found in EGFR, KRAS, BRAF or MET.
Tumors of the thymus represent a diverse collection of
rare thoracic malignancies. The current WHO histological
classification is based on assuming different cell types of
origin, suggesting that these are likely to represent distinct
diseases. Types A, AB, and B1 cluster together because of
their good prognosis. Types B2, B3 and C, the last two of
which represent well and poorly differentiated squamous
carcinomas, respectively, have poorer prognoses. Recent mo-
lecular profiling of 45 thymic tumors from Memorial Sloan
Kettering showed that 1 of 38 thymomas and 1 of 7 thymic
carcinomas were KRAS mutant; 2 of 7 thymic carcinomas
were cKIT mutant (with in vitro evidence of imatinib and
sunitinib sensitivity); but no EGFR mutations were detected.
Some smaller series have detected rare exon 21 and exon 18
mutations in thymomas but never in thymic carcinomas. By
IHC, IGF1R appears to be commonly expressed in both
thymomas and thymic carcinomas, raising additional possi-
bilities to explore with targeted therapies in the clinic.
Targeting the JAK/STAT Pathway
The potential importance of the janus kinase (JAK) and
signal transducer and activator of transcription (STAT) path-
way was discussed. JAK/STAT signaling can be a common
pathway activated by diverse upstream signaling proteins,
including growth factor receptors, cytokines, and non-recep-
tor tyrosine kinases such as SRC and ABL. STAT proteins, in
particular STAT3, are oncogenic in part by activating a gene
transcription program that affects multiple cancer hallmarks.
This includes cell proliferation (cyclin D, Myc), anti-apop-
totic signaling (Mcl-1, Bcl-xL), angiogenesis (VEGF), and
immune evasion (16). While non-tumor cells have robust
systems to allow for only transient activation of this pathway,
tumor cells acquire persistent pathway activation through
various mechanisms. Targeting strategies such as small mol-
ecule inhibitors, natural products, RNA interference, and
tyrosine kinase inhibitors are potential strategies to target
STAT3 signaling in cancer. A JAK kinase inhibitor,
AZD1480, was shown to have selective activity against Jak2
that suppressed tyrosine phosphorylation, DNA binding, and
nuclear translocation of STAT3 (17). Activity of this agent
was shown in mouse tumor models. Other approaches include
developing compounds that target the STAT3 molecule itself,
including agents that inhibit STAT3 dimerization (necessary
for gene transcription) and DNA binding. Studies with animal
tumor models suggest that dual STAT3 and tyrosine kinase
inhibitors may be a rationale strategy to induce tumor cell
death. As opposed to structure-based development of STAT3
inhibitors, another approach is using chemical libraries of
compounds to identify STAT3 inhibitors in a large scale
screen. Preliminary compounds have been identified that
inhibit STAT3 transcriptional activity and further studies are
investigating both mechanisms as well as translational strat-
egies to use these compounds in early phase clinical trials. It
was pointed out the importance of incorporating pharmcody-
namic studies in early phase trials to assess STAT3 target
inhibition. Finally, increasing evidence suggests that STAT3
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activation may be resistance mechanism in lung cancer cells
facing tyrosine kinase inhibitors such as SRC kinase inhibi-
tors (18). A combination of in vitro, in vivo, and human
tumor studies suggests that dual SRC and STAT3 inhibitor
studies should be considered for early phase trials. Overall
the results of this session suggest near term deployment of
STAT3 inhibitors in clinical trials and suggest dual tyrosine
kinase inhibitor plus STAT3 inhibitor strategies are worth
further consideration.
Advocacy, Regulatory, and Funding Issues
An important component of this meeting was the ses-
sion on Advocacy. This included presentations by Laurie
Monroe, a lung cancer survivor and patient advocate, and Dr.
Joan Schiller, head of the National Lung Cancer Partnership.
Amongst the topics discussed were efforts at patient educa-
tion, advocacy for research funds for lung cancer, and iden-
tifying mechanisms for promoting cooperation between pa-
tient advocates and lung cancer researchers.
Cancer Stem Cells
There is growing evidence that a rare subpopulation of
undifferentiated cells which exhibit self-renewal, tumor ini-
tiation and propagation properties exists for lung cancer.
Although the markers to identify these subsets are not fully
known, these cells have been shown to express CD133,
ALDH, Oct-4 and c-kit, in addition to other markers. Within
the tumor and its microenvironment, signaling events through
pathways such as Notch are associated with accumulation of
these cells, and blocking this pathway can lead to a decrease
in ALDH cells. Moreover, inherited and acquired genetic or
epigenetic alterations may modulate groups of genes leading
to propagation of these self-renewing cells. Although cyto-
toxic agents can kill cancer cells, cancer stem cells likely
remain behind to repopulate and migrate, and novel ap-
proaches for inhibiting cancer stem cells are needed. Revers-
ing the process of hypermethylation and histone acetylation
through pharmacologic agents such as 5-aza-2’-deoxycyti-
dine and histone deacetylase inhibitors has the potential to
inhibit these stem cell populations from proliferating and
spreading. In addition, targeting cytokine pathways such as
stem cell factor-c-kit signaling can inhibit lung cancer stem
cells and may improve the efficacy of standard chemothera-
peutic agents (19). Self-renewing cancer cells may result
from asymmetric cell division resulting in a heterogeneous
population of cells within the tumor, and this process has
been described in lung cancer (20). During asymmetric cell
division, stem cell markers such as CD133 segregated with
template DNA while differentiation markers segregated to the
opposite cell. Modulation of this process could lead to novel
therapies to inhibit the replication of self-renewing cells.
Additional insight has been gained through the evaluation of
drug-resistant side population cells which demonstrate in-
creased migration and invasive behavior and have elevated
Rac1-GTP activity. Cell migration and lung colonization can
be blocked by inhibiting Rac1 –GTP signaling. Furthermore,
these side-population cells appear to be a distinct population
of self-renewing cells that do not express CD133, leading to
the hypothesis that multiple populations of self-renewing
cells may exist.
Genome-wide Approaches to Risk
Common cancers tend to cluster in families through
inherited effects. Some are well recognized and strong pre-
disposing genetic mutations (ie: BRCA1 and 2) however,
most are due to individually small but combined effects of
different (common or rare) variants (polygenic model of
cancer susceptibility) yet unexplained. Another small amount
of common variations (6% in breast cancer and 18% in
prostate cancer) have been identified by genome-wide asso-
ciation studies (GWAS). Practical applications to the identi-
fication of genetic variations include the discovery of new
targets for intervention and the creation, in combination with
other (clinical) risk models, of profiles that allow for popu-
lation risk stratifications. This is useful to individuals, public
health officials and researchers for personalized therapy,
screening programs or prospective interventional studies re-
spectively. GWAS have identified factors that contribute to
nicotine dependence and smoking quantity and to the risk of
lung cancer and results from these studies converge on the
same chromosome 15, where the most compelling evidence
of risk lies in the region of the a5-a3-b4 nicotine receptor
gene. Two distinct genetic variants have been implicated in
the a5 receptor subunit; rs 16969968 (causes an amino acid
change resulting in a differential response) and rs588765
(contributes to different expression of a5 in the brain). This
implicates the nicotine receptor a5 subunit as a major genetic
contributor to both disorders. Additional genetic variations
associated with lung cancer risk have been identified in
chromosomes 5 (rs401681) and 6 (rs3117582) and large
cohort studies are ongoing trying to identify common genetic
variants affecting lung cancer and COPD risk (COPDGene).
Lung Cancer Profiling with microRNAs
MicroRNAs (miRNAs) are small, endogenously ex-
pressed non-coding RNAs sequentially processed from
primary transcripts, which regulate protein-coding gene
expression through either translational supression or RNA
degradation (bind messenger RNA at complementary sites in
the 3’ untranslated region). They function either as tumor
suppressors or oncogenes and thus, play an important role in
carcinogenesis. Furthermore, through miRNA expression
profiling, prognostic and predictive biomarkers can be iden-
tified. Several miRNAs have been implicated in the patho-
genesis of lung cancer. The let-7 miRNA family inversely
regulates KRAS and is frequently downregulated in lung
cancer (low let-7 upregulates KRAS). Low levels of let-7
predict for poor outcome (shortened postoperative survival),
likely due to KRAS upregulation. Similarly, rs61764370, a
germline SNP in a let-7 miRNA, present in 7% of the general
population but in 20% of NSCLC patients, predicts for
increased risk of NSCLC and is associated with increased
KRAS expression and decreased let-7 levels. Also, miR-
125a-3p is suppressed in KRAS mutated HBECs and NSCLC
cell lines, but when overexpressed it blocks proliferation of
KRAS mutated HBECs. Conversely, the miR-17–92 cluster
is frequently overexpressed in SCLC. It cancels the genera-
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tion of reactive oxygen species induced by Rb inactivation
and presumably plays a role in SCLC development. Together,
these strongly suggest the role of tumor suppressor-type and
oncogene-type miRNA alterations in the molecular pathogenesis
of human lung cancers. Applications of miRNA profiling in-
clude signatures to predict prognosis (worse with miR17-92
overexpression in resected stage I adenocarcinomas), histology
(miR-205 for adenocarcinoma vs. squamous cell carcinoma and
miR-301, 183 and 126 for NSCLC vs. SCLC) and therapy
resistance (miR92a2*, miR-147 and miR-574–5p in SCLC and
miR-424 for vandetanib and erlotinib and miR-21 for sunitinib
in NSCLC).
Mouse Models of Lung Cancer
In the mouse models of lung cancer section, multiple
speakers highlighted the strengths of genetically engineered
mouse (GEM) lung cancer models to genetically dissect the
roles of different oncogenes and tumor suppressor in lung
cancer initiation and progression. More importantly these
GEM lung cancer models were shown to be great platforms
for testing of novel therapeutics that targeted specifically the
oncogenic drivers of the specific models or its immediate
downstream pathways. Examples of mouse clinical trials with
GEM models and novel targeted therapeutics as well as
conventional chemotherapy were demonstrated in presenta-
tions of Dr. Kwok-Kin Wong and Dr. Leisa Johnson. In
addition, Dr. Minh To presented his elegant mouse genetic
work which dissected the role of the various Kras isoforms in
lung cancer initiation and progression. Lastly, Dr. Yifeng Xia
presented his technology platform of employing lenti-viral
gene delivery to generate de-novo lung cancer.
Other Biomarkers
In this session, a range of topics was addressed cover-
ing a variety of biomarkers and discovery platforms. Pro-
teomics biomarkers were discussed by Drs. David Carbone
and Rachel Ostroff. Dr. Carbone and colleagues used a
variety of mass spectrometry-based platforms to uncover
candidate biomarkers for risk assessment, early diagnosis,
and prediction of response to therapy. One of these, the serum
MALDI-TOF assay predictive of benefit from EGFR-targeted
therapies in lung cancer is now a commercial product, Ver-
istrat. Data were presented that not only is this test useful in
identifying advanced lung cancer patients who benefit from
erlotinib and gefitinib, but also the combination of erlotinib
and bevacizumab. Perhaps surprisingly, good classification
was also observed for lung, head and neck, and colon cancer
patients treated with these drugs, as well as cetuximab. Dr.
Ostroff discussed exciting data using their aptamer platform
to uncover a serum diagnostic for lung cancer. A pattern of
proteins was found that was highly accurate in distinguishing
patients from cancer from those without. Dr. Gower pre-
sented his data extending the data of Dr. Spira evaluating the
gene expression pattern in histologically normal bronchial
epithelium as a biomarker for the presence or absence of lung
cancer. He described a new method, dubbed openSESAME,
that allows the cross-experiment and cross-disease type anal-
ysis of data from GEO to ask or test signature hypotheses. He
showed data that this was useful in the analysis of patterns
from lung, bladder, and head and neck cancer. Dr. Hirsch
discussed his data on IGF1R expression and amplification in
relation to benefit from targeted inhibitors, and Dr. Tsao
presented his exciting data from NCIC randomized clinical
trials defining and testing his microarray signature of benefit
from adjuvant chemotherapy.
In summary, this session demonstrated the wide range
of platforms and biospecimen sources being used to define
potentially clinically useful biomarkers, and presented some
exciting new specific candidate signatures for lung cancer.
Angiogenesis and the Tumor
Microenvironment
Topics for this session included an overview of anti-
angiogenesis agents and their corresponding targets, devel-
opment of a molecular signature for bevacicumab using
molecular and clinical data from patient-based clinical trials,
examining the effects of different anti-angiogenic drugs (in-
cluding tyrosine kinase inhibitors and antibody-based ther-
apies) on early- versus late-stage lung cancer, and identi-
fication of tumor-derived factors that mediate resistance to
anti-vascular endothelial growth factor-based therapies in
NSCLC.
Drug Design and New Targets
The MD Anderson BATTLE program was discussed as
a possible route for personalized therapy in lung cancer using
an adaptive design to allocate treatment decisions with mo-
lecular targeting agents using tumor biomarkers. Other ap-
proaches towards personalizing chemotherapy for advanced
lung cancer were discussed, including ERCC1- and RRM1-
based biomarker strategies, as well as strategies attacking
new targets for the chemoprevention of lung cancer.
Summary
The meeting provided a unique lung cancer focused
translational science meeting that brought together various
experts and stakeholders in lung cancer research. The meet-
ing had breadth by examining a number of unique technolo-
gies for tumor profiling, including both genomic and pro-
teomic approaches, as well as examined tumor biology from
early pre-neoplastic changes to targeting tumor pathways in
metastatic and advanced stages of disease. Tentative plans are
to have this meeting every other year. One theme of this
meeting is the emerging picture of uniqueness amongst lung
cancer defined by molecular subtyping offered by emerging
technologies and the ability to optimize patient care through
an improved understanding of each individual’s tumor biol-
ogy. As this approach is showing promise, the deployment of
novel therapeutic and preventative strategies will benefit from
continued efforts in molecular profiling of lung cancer.
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